PRME.US Prime Medicine, Inc. Common Stock

Healthcare Biotechnology USA Stocks
3.84 USD
Close of Nov 17, 2026
2.67 5.91
Market cap
USD 856M
P/E
-
P/B
112.05x
ROE
-2,058.8%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is PRME.US undervalued?

Graham number

The Graham number of Prime Medicine, Inc. Common Stock cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Prime Medicine, Inc. Common Stock fundamental analysis

No fundamental analysis for Prime Medicine, Inc. Common Stock yet.

Prime Medicine, Inc. Common Stock stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Prime Medicine, Inc. Common Stock

Prime Medicine, Inc., a biotechnology company, engages in delivering genetic medicines to address the spectrum of diseases by deploying gene editing technology in the United States. Its lead therapeutic product candidate is PM359 for Chronic Granulomatous Disease, which is in Phase 1/2 clinical trial; PM577 for Wilson Disease, that is in preclinical studies; and PM647 to treat genetic disorder caused by mutations in the SERPINA1 gene, resulting in production of misfolded Z-A…

Full company profile